Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Doriano Fabbro

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Molecular Pharmacology|January 1, 2015
25 years of small molecular weight kinase inhibitors: potentials and limitationsDoriano Fabbro
International Journal of Molecular Sciences|November 23, 2019
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic DiseasesPetra Hillmann, Doriano Fabbro
IUBMB Life|May 23, 2020
IUBMB focused meeting: 10<sup>th</sup> conference Inhibitors of Protein Kinases. Kinase inhibitors in target biology and disease (IPK2019)Jaroslaw Poznanski, Doriano Fabbro
Expert Review of Anticancer Therapy|December 21, 2004
Targeting protein kinases in cancer therapy: a success?Mark A Pearson, Doriano Fabbro
Methods in Enzymology|November 18, 2014
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidateNathanael S Gray, Doriano Fabbro
Current Opinion in Drug Discovery & Development|March 13, 2003
Targeting protein kinases in cancer therapyDoriano Fabbro, Carlos García-Echeverría
Mini Reviews in Medicinal Chemistry|March 23, 2004
Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinasesCarlos García-Echeverría, Doriano Fabbro
Pharmacological Research|June 6, 2007
Classical PKC isoforms in cancerGeorg Martiny-Baron, Doriano Fabbro
Current Opinion in Pharmacology|July 20, 2002
Protein tyrosine kinase inhibitors: new treatment modalities?Doriano Fabbro, David Parkinson, Alex Matter
Current Opinion in Drug Discovery & Development|October 27, 2004
Structural insights into the conformational selectivity of STI-571 and related kinase inhibitorsClifford D Mol, Doriano Fabbro, David J Hosfield
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Molecular Pharmacology|January 1, 2015
25 years of small molecular weight kinase inhibitors: potentials and limitationsDoriano Fabbro
International Journal of Molecular Sciences|November 23, 2019
PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic DiseasesPetra Hillmann, Doriano Fabbro
IUBMB Life|May 23, 2020
IUBMB focused meeting: 10<sup>th</sup> conference Inhibitors of Protein Kinases. Kinase inhibitors in target biology and disease (IPK2019)Jaroslaw Poznanski, Doriano Fabbro
Expert Review of Anticancer Therapy|December 21, 2004
Targeting protein kinases in cancer therapy: a success?Mark A Pearson, Doriano Fabbro
Methods in Enzymology|November 18, 2014
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidateNathanael S Gray, Doriano Fabbro
Current Opinion in Drug Discovery & Development|March 13, 2003
Targeting protein kinases in cancer therapyDoriano Fabbro, Carlos García-Echeverría
Mini Reviews in Medicinal Chemistry|March 23, 2004
Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinasesCarlos García-Echeverría, Doriano Fabbro
Pharmacological Research|June 6, 2007
Classical PKC isoforms in cancerGeorg Martiny-Baron, Doriano Fabbro
Current Opinion in Pharmacology|July 20, 2002
Protein tyrosine kinase inhibitors: new treatment modalities?Doriano Fabbro, David Parkinson, Alex Matter
Current Opinion in Drug Discovery & Development|October 27, 2004
Structural insights into the conformational selectivity of STI-571 and related kinase inhibitorsClifford D Mol, Doriano Fabbro, David J Hosfield
Pageof 13